Granules India Ltd, a key player in the pharmaceutical industry, has been recommended by Share India with a buy range of ₹590-610 and a target price of ₹770, offering a potential upside of 26%. The company is projected to grow at a CAGR of 34% from FY24 to FY26, backed by its strong market position in the U.S. for CNS/ADHD products and continued expansion in oncology and other high-margin segments.
Key Highlights:
- Granules India is focusing on backward integration, large-volume production, and product portfolio expansion, including 16-18 new product launches expected by FY25.
- The company is a market leader in the U.S. for CNS/ADHD-related products, contributing to 70% of GPI’s revenue, ensuring steady growth.
- Granules is also expanding its manufacturing capabilities with a new facility in Genome Valley, Hyderabad, which will support long-term growth in finished dosage forms.
- The company’s EBITDA margins saw significant improvement, reaching 22% in Q1 FY25, driven by higher-margin finished dosage sales.
With a strong foothold in high-demand therapeutic areas and strategic expansion plans, Share India recommends accumulating Granules India for its long-term growth potential.
Disclaimer: Stock investments are subject to market risks. Please read all related documents carefully before investing. The information provided in this article is for informational purposes only and should not be construed as financial advice. Consult your financial advisor before making any investment decisions.
